EMA Turns Down 3 Therapies Across Oncology, Transplantation Edited by Joyani Das

https://www.medscape.com/viewarticle/ema-turns-down-3-therapies-across-oncology-transplantation-2026a1000lzz?src= The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended refusing marketing authorization for three investigational therapies for cancer and transplant-related conditions: Tacquell (autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded; Netherlands Cancer Institute), Yartemlea (narsoplimab; Omeros Ireland Limited), and Xervyteg (allogeneic fecal microbiota, pooled; MaaT Pharma).